ABMT (Advanced BioMedical Technologies) Cyclically Adjusted Revenue per Share: $0.00 (As of Jul. 2021)


What is Advanced BioMedical Technologies Cyclically Adjusted Revenue per Share?

Advanced BioMedical Technologies ABMT Cyclically Adjusted Revenue per Share is $0.00 as of Jul. 2021.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Advanced BioMedical Technologies's adjusted revenue per share for the three months ended in Jul. 2021 was $0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Jul. 2021.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-11), Advanced BioMedical Technologies's current stock price is $0.0005. Advanced BioMedical Technologies's Cyclically Adjusted Revenue per Share for the quarter that ended in Jul. 2021 was $0.00. Advanced BioMedical Technologies's Cyclically Adjusted PS Ratio of today is .


Advanced BioMedical Technologies  (OTCPK:ABMT) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Advanced BioMedical Technologies Cyclically Adjusted Revenue per Share Related Terms


Advanced BioMedical Technologies Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Advanced BioMedical Technologies's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Advanced BioMedical Technologies Cyclically Adjusted Revenue per Share Chart

Advanced BioMedical Technologies Annual Data
Trend Oct11 Oct12 Oct13 Oct14 Oct15 Oct16 Oct17 Oct18 Oct19 Oct20
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Advanced BioMedical Technologies Quarterly Data
Oct16 Jan17 Apr17 Jul17 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ABMT vs VYCO, ADMT, THMO: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Advanced BioMedical Technologies's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Advanced BioMedical Technologies Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Advanced BioMedical Technologies's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Advanced BioMedical Technologies's Cyclically Adjusted PS Ratio falls into.



Advanced BioMedical Technologies Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Advanced BioMedical Technologies's adjusted Revenue per Share data for the three months ended in Jul. 2021 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jul. 2021 (Change)*Current CPI (Jul. 2021)
=0/273.0030*273.0030
=0.000

Current CPI (Jul. 2021) = 273.0030.

Advanced BioMedical Technologies Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201110 0.000 226.421 0.000
201201 0.000 226.665 0.000
201204 0.000 230.085 0.000
201207 0.000 229.104 0.000
201210 0.000 231.317 0.000
201301 0.000 230.280 0.000
201304 0.000 232.531 0.000
201307 0.000 233.596 0.000
201310 0.000 233.546 0.000
201401 0.000 233.916 0.000
201404 0.000 237.072 0.000
201407 0.000 238.250 0.000
201410 0.000 237.433 0.000
201501 0.000 233.707 0.000
201504 0.000 236.599 0.000
201507 0.000 238.654 0.000
201510 0.000 237.838 0.000
201601 0.000 236.916 0.000
201604 0.000 239.261 0.000
201607 0.000 240.628 0.000
201610 0.000 241.729 0.000
201701 0.000 242.839 0.000
201704 0.000 244.524 0.000
201707 0.000 244.786 0.000
201710 0.000 246.663 0.000
201801 0.000 247.867 0.000
201804 0.000 250.546 0.000
201807 0.000 252.006 0.000
201810 0.000 252.885 0.000
201901 0.000 251.712 0.000
201904 0.000 255.548 0.000
201907 0.000 256.571 0.000
201910 0.000 257.346 0.000
202001 0.001 257.971 0.001
202004 0.000 256.389 0.000
202007 0.000 259.101 0.000
202010 0.001 260.388 0.001
202101 0.001 261.582 0.001
202104 0.000 267.054 0.000
202107 0.000 273.003 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $0.00 mean?
Advanced BioMedical Technologies (ABMT) has a Cyclically Adjusted Revenue per Share of $0.00 as of Jul. 2021. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Advanced BioMedical Technologies and its competitors.
Is Advanced BioMedical Technologies' Cyclically Adjusted Revenue per Share too high?
Advanced BioMedical Technologies' current Cyclically Adjusted Revenue per Share is $0.00.
How does Advanced BioMedical Technologies' Cyclically Adjusted Revenue per Share compare to VYCO and ADMT?
Advanced BioMedical Technologies' Cyclically Adjusted Revenue per Share of $0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Advanced BioMedical Technologies and its competitors. Advanced BioMedical Technologies's current Cyclically Adjusted Revenue per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Advanced BioMedical Technologies stock overvalued right now?
Advanced BioMedical Technologies (ABMT) has a current Cyclically Adjusted Revenue per Share of $0.00. The current Cyclically Adjusted Revenue per Share is $0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Advanced BioMedical Technologies (ABMT), the current Cyclically Adjusted Revenue per Share is $0.00 as of Jul. 2021. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Advanced BioMedical Technologies Business Description

Address 535 Fifth Avenue, 4th Floor, New York, NY, USA, 10017
Advanced BioMedical Technologies Inc is engaged in designing, developing, manufacturing, and the planned future marketing of self-reinforced, re-absorbable, biodegradable internal fixation devices. The company manufactures its products using Polyamide, and it is used in a variety of applications, which include orthopaedic trauma, sports-related medical treatment, cartilage injuries, and reconstructive dental procedures. Its Polyamide products include screws, rods, and binding wires consisting of enhanced fibres and high molecular polymers, which are designed to facilitate quick healing of complex fractures in many areas of the human skeletal system.